• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by OptimizeRx Corporation

    11/28/23 4:10:08 PM ET
    $OPRX
    Business Services
    Consumer Discretionary
    Get the next $OPRX alert in real time by email
    SC 13G 1 ea189150-13gweintraub_optim.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    OptimizeRx Corporation

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    68401U204

    (CUSIP Number)

     

    October 24, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)
    ☒Rule 13d-1(c)
    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP NO.  68401U204 Schedule 13G Page 2 of 5

     

    1

    NAMES OF REPORTING PERSONS

     

    Michael Weintraub

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     

    (a)     ☐
    (b)     ☐
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:

    5

    SOLE VOTING POWER

     

    1,384,467

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    1,384,467

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,384,467

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)     ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    7.6%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

     

     

    Page 3 of 5

     

    Item 1(a)Name of Issuer:

     

    OptimizeRx Corporation (the “Issuer”)

     

    Item 1(b)Address of Issuer’s Principal Executive Offices:

     

    260 Charles Street, Suite 302, Waltham, MA 02453

     

    Item 2(a)Name of Person Filing:

     

    Michael Weintraub (the “Reporting Person”)

     

    Item 2(b)Address of Principal Business Office or, if none, Residence:

     

    10799 N 90th Street, Suite 200

    Scottsdale, AZ 85260

     

    Item 2(c)Citizenship:

     

    United States of America

     

    Item 2(d)Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (“Common Stock”)

     

    Item 2(e)CUSIP Number:

     

    68401U204

     

    Item 3Not Applicable

     

    Item 4Ownership:

     

    The following describes the ownership of Common Stock by the Reporting Person as of October 24, 2023:

     

    (a)Amount beneficially owned: 1,384,467 shares of Common Stock.

     

    The filing of this Schedule 13G shall not be construed as an admission that (a) the Reporting Person is, for purposes of Section 13(d) or 13(g) of the Act, the beneficial owner of any equity securities covered by this Schedule 13G or (b) that this Schedule 13G is legally required to be filed by the Reporting Person.

     

    (b)Percent of class: 7.6% (based on 18,148,829 shares of Common Stock outstanding as of October 24, 2023)

     

     

     

     

    Page 4 of 5

     

    (c)Number of shares as to which the Reporting Person has:

     

    (i)sole power to vote or to direct the vote: 1,384,467

     

    (ii)shared power to vote or to direct the vote: 0

     

    (iii)sole power to dispose or to direct the disposition of: 1,384,467

     

    (iv)shared power to dispose or to direct the disposition of: 0

     

    Item 5Ownership of Five Percent or Less of a Class:

     

    Not Applicable

     

    Item 6Ownership of More Than Five Percent on Behalf of Another Person:

     

    Not Applicable

     

    Item 7Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Not Applicable

     

    Item 8Identification and Classification of Members of the Group:

     

    Not Applicable

     

    Item 9Notice of Dissolution of Group:

     

    Not Applicable

     

    Item 10Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    Page 5 of 5

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: 11/28/2023   By: /s/ Michael Weintraub
            Name:  Michael Weintraub

     

     

     

     

     

     

    Get the next $OPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPRX

    DatePrice TargetRatingAnalyst
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    12/20/2024$5.50Equal-Weight
    Stephens
    7/25/2024$18.50Buy
    B. Riley Securities
    4/4/2024$15.00Mkt Outperform
    JMP Securities
    1/3/2024$15.00Equal Weight
    Barclays
    2/2/2023$30.00Buy
    B. Riley Securities
    11/1/2022$19.00Buy
    Stifel
    7/15/2022$38.00Outperform
    SVB Leerink
    More analyst ratings

    $OPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

      SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

      12/6/24 4:26:03 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G filed by OptimizeRx Corporation

      SC 13G - OptimizeRx Corp (0001448431) (Subject)

      11/14/24 3:18:35 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

      SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

      11/14/24 11:25:34 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment

      WALTHAM, Mass., April 18, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that, as part of OptimizeRx's ongoing process to refresh and expand its board of directors (the "Board"), it intends to appoint a new independent director to its Board of Directors during the second half of this year.  With the appointment of a new independent director in 2025, OptimizeRx will have refreshed its Board, which is currently comprised of five directors, with three new directors since 2020, including Catherine Klema w

      4/18/25 4:15:53 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer

      WALTHAM, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced it has appointed Steve Silvestro as the Company's new Chief Executive Officer, effective March 10, 2025. Mr. Silvestro brings to OptimizeRx more than 20 years of experience in building and managing health technology and services companies, and has served as an executive at OptimizeRx since joining the Company in 2019. His career includes strategic development, sales leadership, technology and product innovation, and M&A within a

      3/10/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO

      WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that William J. Febbo, Chief Executive Officer (CEO) and Board Member, will be departing the Company, effective as of December 31, 2024, to pursue other opportunities. Mr. Febbo will provide the Company with advisory services through March 31, 2025. The Company's Board of Directors has retained a search firm to assist in this transition. "The time is right to pass the reins on to an incredible team, ready to carry the legacy forwa

      12/23/24 8:45:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      3/19/25 7:40:24 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • CEO Febbo William J bought $100,220 worth of shares (20,000 units at $5.01), increasing direct ownership by 3% to 601,253 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      12/16/24 2:28:39 PM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • OptimizeRx downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously

      1/8/25 8:17:01 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Stephens initiated coverage on OptimizeRx with a new price target

      Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50

      12/20/24 7:46:38 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • B. Riley Securities resumed coverage on OptimizeRx with a new price target

      B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50

      7/25/24 8:24:56 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by OptimizeRx Corporation

      10-Q - OptimizeRx Corp (0001448431) (Filer)

      5/13/25 4:04:23 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OptimizeRx Corp (0001448431) (Filer)

      5/12/25 4:08:06 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Amendment: SEC Form SCHEDULE 13G/A filed by OptimizeRx Corporation

      SCHEDULE 13G/A - OptimizeRx Corp (0001448431) (Subject)

      4/30/25 11:22:15 AM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Greco Theresa was granted 9,483 shares, increasing direct ownership by 19% to 60,356 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      5/19/25 4:04:14 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Chief Commercial Officer Silvestro Stephen L was granted 46,948 shares, increasing direct ownership by 39% to 168,262 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      5/19/25 4:03:33 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

      4 - OptimizeRx Corp (0001448431) (Issuer)

      3/19/25 7:40:24 PM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OptimizeRx to Participate in Upcoming Investor Conferences

      WALTHAM, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: B. Riley Securities 25th Annual Investor Conference, Marina del Rey, May 21 – 22, 2025Stifel 2025 Boston Cross Sector 1x1 Conference, Boston, June 3 – 4, 202545th Annual William Blair Growth Stock Conference, Chicago, June 3 – 5, 2025The Citizens Medical Devices and Healthcare Services Forum, Boston, June 17, 2025 B. Riley Securities 25th Annual Invest

      5/16/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

      Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended March 31, 2025. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2025

      5/12/25 4:05:00 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report

      WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2025. As a company focused on optimizing meaningful engagement opportunities at critical junctures of the healthcare journey, we remain dedicated to aligning our mission with our responsibilities as a corporate citizen. "Our stakeholders continue to expect us to transparently disclose our commitment to environmental, social, and governance responsibilities," stated Marion

      5/1/25 4:05:00 PM ET
      $OPRX
      Business Services
      Consumer Discretionary

    $OPRX
    Financials

    Live finance-specific insights

    See more
    • OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

      Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended March 31, 2025. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2025

      5/12/25 4:05:00 PM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET

      WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Monday, May 12, 2025, at 4:30 p.m. Eastern Time to discuss its results for the first quarter period ended March 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Monday, May 12, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Toll Free

      4/23/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary
    • OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results

      Q4 revenue of $32.3 million, increasing 14% year-over-yearQ4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68%Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023 WALTHAM, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024.  For the Year EndedDecember 31,Key Performance Indicators (KPIs)* 2024   2023  (in thousands, except percentages)Average revenue per top 20 pharma

      3/12/25 7:30:00 AM ET
      $OPRX
      Business Services
      Consumer Discretionary